Kelly Fitzgerald, MD, BA

Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer 2023. PMID: 37864521

Fitzgerald KN, Motzer RJ, Lee CH. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nature reviews. Urology 2022. PMID: 36369389

Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European urology 2022. PMID: 36344318

Fitzgerald KN, Lee CH. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35385828

Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European urology focus 2022. PMID: 35288096

Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leukemia & lymphoma 2021. PMID: 34949132

Fitzgerald, K and Daud, A.. J Clin Oncol Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma. 2019. PMID:

Fitzgerald K, Tsai KK. Systemic therapy for advanced cutaneous squamous cell carcinoma. Seminars in cutaneous medicine and surgery 2019. PMID: 31051028

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science (New York, N.Y.) 2016. PMID: 26966191

Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. A comparison of non-integrating reprogramming methods. Nature biotechnology 2014. PMID: 25437882